Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. ACN
3. IBM
4. MU
5. NVDA
6. PRIM
7. META
8. SPY
9. SPCX
10. DPZ

Go back to Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy
(NASDAQ: KURA) Delayed: 10.44 +0.08 (0.77%)
Previous Close $10.36    52 Week High $8.90 
Open $10.18    52 Week Low $2.50 
Day High $10.51    P/E N/A 
Day Low $10.18    EPS $0.00 
Volume 80,944